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Academic paediatrics: Easter Island or
Easter Sunday?
J Savill
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Commentary on the paper by Levene and Olver (see page 450)
W
hen the last tree on Easter
Island was felled, the inhabi-
tants belatedly realised that
there was no escape from an eon of
‘‘groundhog days’’. Paediatrics, a disci-
pline championed in the UK, faces a
comparably monotonous future bereft
of innovation and improvement. Levene
and Olver present alarming data on
staffing changes in UK academic pae-
diatrics between 1999 and 2004.1 Most
worrying is a 26% reduction in the stock
of clinical lecturers, the academic sap-
lings crucial to the future health of the
paediatric wood. Is there hope for this
dying research discipline? Yes, but only
if paediatrics joins the main forest of
clinical academic medicine in pursuit of
research excellence, the surest protec-
tion against research assessment exer-
cise (RAE) related tree felling—loss of
life seems more threatening than loss of
identity. Young paediatricians will win
coveted research training and clinician
scientist fellowships if they are sup-
ported in spending time in major
research centres working at critical mass
(although academic medicine sorely
needs more fellowships available, espe-
cially at the post-doctoral level).
Furthermore, establishment of the joint
Academic Medicine Sub-committee of
Modernising Medical Careers and the
UK Clinical Research Collaboration (UK
CRC) promises the design and imple-
mentation of an integrated, flexible
clinical academic career track for good
clinicians who excel in research and/or
teaching. Paediatrics must participate,
particularly as UK CRC will establish
research networks for medicines in
children. Rather than the bleak prospect
of Easter Island, I look forward to an
Easter Sunday for academic paediatrics,
a resurrection of a highly respected dis-
cipline in a form that is even more influ-
ential and all-pervasive than before.
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Pyridoxine or pyridoxal phosphate for
intractable seizures?
P Baxter
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Commentary on the paper by Wang et al (see page 512)
T
he short answer is pyridoxal phos-
phate, but before reaching for the
prescription pad it’s worth look-
ing at the context. Intractable seizures
have no set definition.1 One practical
approach is to review management
when seizures continue despite the use
of two appropriate anticonvulsants at
maximum tolerated doses. Points to
consider include whether the diagnosis
is correct, as syncope and other non-
epileptic events can still mislead; the
cause of the seizures, for example
structural, chromosomal, neurodegen-
erative, or metabolic conditions;
whether there is an avoidable precipi-
tant; whether the choice of drug and
dose were correct, as for example
carbamazepine can exacerbate some
primary generalised epilepsies; and
compliance.1 Treatment options include
other anticonvulsants; drugs such as
vitamins, acetazolamide, or steroids;
IVIG; specific diets; resective and other
types of surgery, the vagal nerve stimu-
lator, and a variety of other approaches
such as yoga, epilepsy dogs, etc.
Pyridoxine dependency is a rare but
well described recessive condition
whose biochemical and genetic cause is
unknown. It classically presents with a
neonatal epileptic encephalopathy but
can present with seizures later in child-
hood as well. For this reason it is
included in the various metabolic ence-
phalopathies with seizures which are
excluded by a trial of vitamins such as
pyridoxine, folinic acid, or biotin.2 As
early treatment may improve the out-
come it could be argued that these
should be used sooner, not after other
drugs have failed. Pyridoxal phosphate
is the major activated form of vitamin
B6, which is a mixture of pyridoxine,
pyridoxal, pyridoxamine and their 59-
phosphates. It is a co-factor in many
enzymatic reactions in the CNS and
elsewhere, particularly amino acid
transamination and decarboxylation.
This includes the formation of biogenic
amines such as noradrenaline and ser-
otonin.3 Pyridoxine from any source is
usually rapidly phosphorylated to the
active form, as shown by the ‘‘end of the
needle’’ response in cases of pyridoxine
dependency. However, two cases have
been described where this process was
defective. These children presented with
a severe neonatal epileptic encephalo-
pathy that only responded to pyridoxal
phosphate.4
Wang et al restrict their study to
children with seizures resistant to three
or more conventional drugs given over a
six month period.5 Despite excluding
structural, chromosomal, infective, or
metabolic disorders, including pyridox-
ine dependency, they have collected an
impressive number of children. Their
data suggest that pyridoxine, and even
more so pyridoxal phosphate, is useful
in this group.
This is particularly so in children with
West syndrome where six of their 13
cases achieved seizure control with
pyridoxine or pyridoxal phosphate. In
countries such as Japan or Germany
these are used routinely as first line
therapy for West syndrome. In four case
series pyridoxine responders totalled
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20% of idiopathic and 5% of sympto-
matic cases, while in two others pyr-
idoxal phosphate responders numbered
25% of idiopathic and 10% of sympto-
matic cases. These series are difficult to
compare as different doses regimens
were used.6 Nonetheless they support
the findings of Wang et al that pyridoxal
phosphate is more effective than
pyridoxine. Interestingly the outcome
appears better in responders than non-
responders.6 7 Obviously response rates
for vigabatrin or steroids are much
higher.8 To complicate matters, other
authors have suggested that adding
pyridoxal phosphate to steroids or
sodium valproate can help achieve
seizure control at lower doses of the
latter drugs.6
Wang et al also report that 2/44
children with generalised and 3/37 with
focal seizures achieved complete seizure
control with pyridoxine or pyridoxal
phosphate. All of these developed epi-
lepsy before the age of 15 months. Six
more had improved seizure control,
although it is not reported what their
ages of onset or seizure types were, and
one had an exacerbation of seizures.
Earlier studies using pyridoxine in chil-
dren resistant to what are now con-
sidered the older anticonvulsants have
not shown very impressive responses.
Livingston and colleagues9 found no
useful response in 31 children;
Hagberg and colleagues10 reported two
out of 26 who achieved complete seizure
control and others with improved con-
trol; Hughes and colleagues11 found
some improvement in four of ten
patients, while Singh and Sinha12 in a
large Indian series reported seizure
control in two out of 120. Jiao and
colleagues13 reported that adding pyri-
doxine to conventional treatment in
acute symptomatic recurrent seizures
of any cause improved outcome. Wang
et al are the first to report using
pyridoxal phosphate in this situation,
again with rather better results in highly
selected patients. Neonatal seizures and
some cases of Ohtahara syndrome form
other special groups where useful
responses can occur.6 14 In all these
situations pyridoxine or pyridoxal phos-
phate appear to have an anticonvulsant
effect, rather than to be treating a
metabolic disorder. It is notable that
younger children appear more likely to
respond. However, rare adult responders
have also been described.6 15
One bonus of pyridoxine or pyridoxal
phosphate therapy is the relative lack of
side effects. In pyridoxine dependency,
even when given orally, pyridoxine can
cause serious acute effects including
apnoea in neonates, but not in older
children. With very high doses in West
syndrome, side effects of either prepara-
tion can include loss of appetite, rest-
lessness and screaming, vomiting and
diarrhoea, apathy and drowsiness. In
adults taking very high doses for periods
of months, a largely reversible sensory
neuropathy (dorsal root ganglionopa-
thy) can occur, but this has only rarely
occurred in children.6 In West syndrome
in particular, this seems important as
both vigabatrin and steroids, while more
effective, may have much more signifi-
cant side effects. Pyridoxal phosphate is
more expensive: in the UK, 50 mg
tablets of pyridoxine and pyridoxal
phosphate cost approximately 2 and 12
pence, respectively.
Wang et al set us a challenge. In
children with intractable seizures, espe-
cially those with an early onset, it
probably is worth giving a course of
pyridoxal phosphate orally at a dose of
50 mg/kg/day for two weeks. This
should be in the context of a full clinical
review. If they respond, pyridoxine
could be substituted as it is cheaper,
providing that it is also effective. In
neonatal seizures and in West syndrome
I believe that pyridoxal phosphate
should be tried early. In the latter I
now give it with vigabatrin at the start
of treatment. However, multicentre ran-
domised controlled trials are needed to
determine its role and value. In other
seizure types the role of pyridoxine or
pyridoxal phosphate has an even smal-
ler evidence base, but at least they are
unlikely to do any harm if given for two
weeks. More importantly, we need more
formal studies of the management of
intractable seizures in children and
neonates.
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Success in tackling deafness with
multi-faceted interventions
A R Gatrad, A Sheikh
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Commentary on the paper by Yoong et al (see page 454)
T
he interface between ethnicity,
health, and health care delivery is
complex, and studying this area is
known to throw up somewhat paradox-
ical findings. In this issue, Yoong and
colleagues raise two important observa-
tions that we wish to comment on,
namely the persistence of consangui-
neous marriage patterns in British
Pakistani Muslim families and, in those
families with children with deafness,
their access to relevant health care
services.1 We consider each of these
issues—the first predictable and the
second unexpected—in turn.
It is now well known among health
professionals that consanguineous kin-
ship patterns increase the risk of reces-
sively inherited disorders such as
congenital deafness. It is estimated that
the birth prevalence of infants with
recessively inherited disorders rises by
about 7 per 1000 for every 0.01 increase
in the coefficient of consanguinity (F).
Among British Muslim Pakistanis, F is
estimated at 0.0431 compared with
0.003 for most North European popula-
tions. But despite this knowledge being
widespread within professionals, it is
our impression that a large proportion of
Britain’s Pakistani Muslim population
remain unaware of the relation between
consanguinity and adverse outcomes.
This may go some way to explaining
why consanguinity persists as a social
practice in this community.
Our belief that the process of accul-
turation (whereby immigrant minorities
begin to take on the characteristics of
the host population) would rapidly lead
to the demise of the acceptable kinship
pattern has not as yet been realised. On
the contrary our experience suggests
that consanguinity is alive and well
and is, if anything, on the increase.
Given the significant increased risk of
death and serious disability associated
with consanguinity it is pertinent here
to consider why this might be so.
It is certainly true that more needs to
be done to make information on the
risks of familial marriage patterns avail-
able to the target populations, and in
this vein there is also a need for health
services to think more creatively about
how best to disseminate this informa-
tion. The burgeoning Asian and Muslim
print, online, and audio/visual media
outlets, for example, offer new and
exciting opportunities to engage mean-
ingfully with these communities.
Importantly, this use of specialist media
outlets should be viewed as additional
to the more traditional approaches, and
not as an alternative to other outlets, as
both are likely to help reach different
sections of these increasingly heteroge-
neous communities.
There is also a need for health
professionals to develop a far more
sophisticated appreciation of why con-
sanguinity exists as a social phenom-
enon, recognising that it offers several
important advantages that cannot be
dismissed lightly. Briefly, these benefits
include a secure mechanism to retain
family wealth and property within a
confined group, as has been used to
considerable effect by British aristocracy
and the royalty. More important per-
haps, in the British Muslim context, is
the belief that marriage of a son or
daughter to a blood tie offers greater
prospect of security for ageing parents
than that which can be expected of some-
one who marries outside the family.2
In order to have credibility among
target populations, it is thus important
that any health promotional interven-
tions, aiming to reduce consanguinity,
accurately reflect the potential advan-
tages and risks associated with consan-
guinity and present this information in
a non-judgemental fashion. The aim of
such interventions must thus always
enable families to make their own
informed decisions in the light of
accurate and unbiased information.
Even in cases where families do wish
to move away from traditional marriage
patterns (on account of an awareness of
the health risks or for other reasons),
this may not always be possible. This is
because migration has, in the short term
at least, fractured many social networks
and therefore made it difficult to find
suitable partners for offspring from
outside the extended family. This may
also in part explain the observed
increases in consanguineous marriages
Taken together, these factors suggest
that the proportion of British Pakistani
Muslims in consanguineous relation-
ships may continue to increase in the
short term. However, as the message of
the risk of adverse outcomes in children
becomes increasingly appreciated and,
furthermore, as these communities
develop established social infrastructures,
it is likely that there will then be a rapid
transition to less introverted marriage
patterns. The emergence of Muslim nur-
sing homes and marriage agencies is, we
believe, indicative of this future trend.
Improving access to health care and
ensuring equitable access for all sections
of the population are national priorities
for the NHS. While many research
teams have highlighted the problems
of poor access in relation to minority
ethnic communities, there have been
relatively few reports of success in
ensuring delivery of high quality care
to these communities, who are typically
those most in need. There have further-
more been a number of reports of diffi-
culties in delivering genetics counselling
to affected families. The paper by Yoong
et al is as far as we are aware the first to
show equitable access to paediatric
audiology and genetics services for
Pakistani Muslims, and therefore makes
welcome reading about a problem that
was highlighted as far back as 1980.3
Importantly, it underscores the message
that, with concerted effort and resources,
it is possible to develop services that meet
the needs of diverse population groups.
The main barriers to equitable provi-
sion of care are structural, reflecting the
fact that the NHS was originally devel-
oped to serve a relatively homogeneous
population. The increasing ethnic, reli-
gious, and cultural diversity of British
society has therefore posed a consider-
able challenge to those involved with
planning and delivering care, although,
as shown by the Stephen Lawrence
enquiry, this problem is not exclusive
to the NHS. Attempts at overcoming
these barriers have hitherto often been
misguided and/or simplistic with the
risk of (unintentionally) alienating the
intended recipients of improved care.
Overcoming barriers to facilitating
access to care therefore requires an in-
depth appreciation of the sociocultural
context in which strategic interventions
are framed.
According to Kai,4 over 7% of the NHS
workforce is from minority groups. If
this group was empowered to reflect or
share their expertise, standards of
health care for this vulnerable popu-
lation could be improved. Cultural
competence is an evolving process that
depends on self-reflection, self-aware-
ness, and acceptance of differences.5
Success in this programme has been
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achieved by beginning to understand
this concept. Also needed is a commit-
ment to working in conjunction with the
intended recipient communities so as to
ensure that any intervention developed
is culturally sensitive. The multi-faceted
nature of the interventions that have
taken place in Bradford—consisting of
population screening for deafness in
neonates, parental education, and invol-
vement and training for health profes-
sionals into ways of working effectively
with diverse populations—reflects this
holistic informed approach to enhancing
service delivery with excellent results.
All this against a background of high
failure rates of attendance for appoint-
ments among the Muslim population.6
While there is an increased uptake of
genetic services among the Bradford
Pakistani population, this appears not
(yet) to have translated into reductions
in the incidence of congenital deafness;
more unexpected and puzzling is the
reason why increasing attendance for
audiology services has resulted in sub-
stantially greater uptake of cochlear
implants than that observed in the
white population. This must, however,
remain a question for another day.
Arch Dis Child 2005;90:443–444.
doi: 10.1136/adc.2004.057182
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New bacteria in cystic fibrosis
I
n recent years new, or relatively new, bacterial isolates have been obtained from patients
with cystic fibrosis (CF). They include Burkholderia cepacia, Stenotrophomonas maltophilia,
Achromobacter xylosidans, and Mycobacterium avium complex. Three papers in Thorax have
added to knowledge about the occurrence and clinical significance of the first two of these
organisms.
S maltophilia (previously known as Pseudomonas, or Xanthomonas, maltophilia) is a Gram-
negative, non-fermenting rod found in the airways of CF patients and with widespread
antibiotic resistance. Its importance as a pathogen has been unclear. A cohort study based
on the US CF Foundation National Patient Registry (CH Goss and colleagues. Thorax
2004;59:955–9) has shown no correlation between S maltophilia colonisation and progression
of lung disease. Among 20 755 patients aged 6 years or older (median age at entry 13.8
years) 2739 (13%) had at least one positive culture for S maltophilia. Patients colonised with
the organism had worse lung function (FEV1 adjusted for sex, height, and age) but S
maltophilia positivity did not influence the rate of decline in lung function after adjustment
for confounding factors. The effect of treatment for S maltophilia needs to be assessed.
Organisms of the Burkholderia cepacia complex can cause serious lung infection in CF
patients. There are nine B cepacia complex species, the commonest of which is B cenocepacia.
The ET12 strain of B cenocepacia has been isolated from patients in Canada and the UK but
the PHDC strain has been confined to the USA. Now workers in Ghent, Belgium (T Coenye
and colleagues. Thorax 2004 59:952–4) have examined 796 B cenocepacia isolates and found
that on randomly amplified polymorphic DNA (RAPD) typing, 19 European isolates were
similar to 14 US reference isolates for the PHDC strain. Rep-PCR using the BOX-A1R primer
(BOX-PCR) confirmed that the European isolates (from eighteen recent clinical samples
from CF patients in France and Italy and one urine sample in the UK from 1964) were of the
same clone as the PHDC strain. The PHDC strain is present on both sides of the Atlantic
ocean.
Researchers at a Manchester centre for adults with CF (AM Jones and colleagues. Thorax
2004;59:948–51) have studied the two most common species (genomovars) of the B cepacia
complex—B cenocepacia and B multivorans. Forty-nine patients had been infected with either
B cenocepacia (33) or B multivorans (16). Chronic infection ensued in 31/33 and 8/16
respectively. One-year survival among patients chronically infected with B cenocepacia was
reduced compared with their Pseudomonas aeruginosa-infected controls (80% vs 100%)
whereas among patients infected with B multivorans survival was the same as among their P
aeruginosa-infected controls (100%). The rates of 5-year survival were 67% vs 85% (B
cenocepacia vs P aeruginosa) and 75% vs 75% (B multivorans vs P aeruginosa).
S maltophilia is not associated with more rapid decline in lung function; B cenocepacia strain
PHDC has crossed the Atlantic; and B cenocepacia, but not B multivorans, is associated with
reduced survival compared with P aeruginosa.
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